Skip to main content
OpenTrials
Completed

NCT Number: NCT00826163

Innate Immune Responses in Chronic Obstructive Pulmonary Disease (COPD) Patients

We hypothesize that ongoing and more severe airway inflammation in COPD may result from the impairment in activation of innate immune response

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kittipong Maneechotesuwan

Bangkoknoi, BKK, 10700, Thailand

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • clinical diagnosis of COPD or asthma
  • a ratio of prebronchodilator FEV1 to forced vital capacity (FVC) equal to or less than 0.70
  • postbronchodilator FEV1 > or = 50% predicted

Exclusion criteria

  • Exacerbation
  • systemic corticosteroids
  • DM, HIV and autoimmune disease
  • immunosuppressive therapy

Treatment and study plan

Budesonide

Drug

Inhaled budesonide 400 mcg twice a day for 2 weeks

Other names: Rhinocort

Primary outcomes

  1. Sputum IL-8, IL-17

    Time frame: 2 WEEKS

Secondary outcomes

  1. The expression of NF-kappa B in sputum macrophages

    Time frame: 2 WEEKS

Sponsors and collaborators

Lead sponsor

Mahidol University

Other

Collaborators

  • National Science and Technology Development Agency, Thailand

Registry information

Official study title

Innate Immune Responses in Chronic Obstructive Pulmonary Disease Patients

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Jan 21, 2009
Registry last updated
Sep 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.